权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of novel inhibitors of C1q for the treatment of Neurodegenerative diseases

开发用于治疗神经退行性疾病的新型 C1q 抑制剂

基本信息

批准号：
9139157
负责人：
Sethu Sankaranarayanan
金额：
$ 121.39万
依托单位：
ANNEXON, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-15 至 2017-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9139157
关键词：
Abeta synthesis Affinity Age Aging-Related Process Alzheimer&apos s Disease Alzheimer&apos s disease model Amyloid beta-Protein Animal Model Anti-Inflammatory Agents Antibodies Award Behavioral Biochemical Brain Brain region Chronic Clinic Clinical Research Clinical Trials Complement Complement 1q Complement Activation Country Data Dementia Dependence Deposition Development Disease Dose Economics Elderly Evaluation Event Excision Frequencies Funding Goals Grant Hippocampus (Brain)Histology Human Learning Measures Medical Medical Economics Memory Memory Loss Memory impairment Mus Nerve Nerve Degeneration Nervous System Physiology Neurodegenerative Disorders Outcome Pathology Pathway interactions Peripheral Phase Pilot Projects Population Preparation Primates Process Proteins Rattus Regimen Research Risk Risk Factors Role Safety Sampling Serum Small Business Innovation Research Grant Social Problems Staging Stroke Synapses Testing Therapeutic Agents Time Toxicology Vaccines Work aging population efficacy testing functional decline in vivo inhibitor/antagonist insight juvenile animal meetings morris water maze mouse model normal aging novel novel therapeutics preclinical study prevent public health relevance social

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the aging population and is a serious unmet medical, social and economic problem worldwide. Current therapies provide only modest symptomatic relief, highlighting the need for better, disease-modifying treatments. The goal is to advance a novel therapeutic agent, ANX005, toward the clinic as a potential treatment for AD. ANX005 inhibits C1q, the initiating molecule of the classical complement cascade. C1q has a critical role in the physical pruning of synapses during development. In addition, C1q accumulates on synapses during normal aging - at levels 300-fold higher than those in younger animals. Abnormal accumulation of C1q may put synapses at risk of damage in a variety of neurodegenerative diseases, leading to synapse loss and a decline in neurologic function. It may also help to explain why age is the most important risk factor for neurodegenerative disease. This work will seek to establish proof of concept that inhibition of C1q will both protect against synapse loss and prevent functional decline in animal models of AD. We will establish appropriate dosing regimens with ANX005 for chronic efficacy testing in mice, as well as dose selection for safety evaluation in both rats and primates. In order to achieve these goals over the course of studies, ANX005 will be dosed in the range of 10-100 mg/Kg, parenterally, once weekly for durations of 1 to 6 months in a mouse models of AD. Efficacy in behavioral endpoints that measure learning and memory, such as the Morris water maze, will be evaluated at the end of the dosing period. Serum, CSF and brain samples will be collected for biochemical and histological evaluation, and levels of ANX005 in serum and CSF will be determined. Target engagement of ANX005 will be evaluated by measuring C1q levels in CSF and in hippocampal and cortical brain regions. Efficacy will be evaluated by quantitative histology of pre and post synaptic markers to demonstrate impact on synapse protection and microglial and astrocytic activation. Successful outcome of this work will allow advancement of ANX005 into early phase clinical studies within the next two years. In addition to demonstration of efficacy in AD mouse models, these preclinical studies will test, on a fundamental level, the hypothesis that preventing synapse loss can slow the progression of neurodegenerative disease, and provide novel insights into the process of neurodegeneration.